Risk of second primary cancer from proton arc therapy of pediatric brain tumors

Proton arc therapy (PAT) is currently explored for clinical implementation, despite its associated low-dose bath. This study therefore aimed at evaluating the risk of radiation-induced second primary cancer (SPC) for PAT in pediatric brain tumor patients. Two brain-specific models for SPC induction...

Descripción completa

Detalles Bibliográficos
Autores principales: Toussaint, Laura, Indelicato, Daniel J, Muren, Ludvig P, Stokkevåg, Camilla H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465935/
https://www.ncbi.nlm.nih.gov/pubmed/37655121
http://dx.doi.org/10.1016/j.phro.2023.100480
Descripción
Sumario:Proton arc therapy (PAT) is currently explored for clinical implementation, despite its associated low-dose bath. This study therefore aimed at evaluating the risk of radiation-induced second primary cancer (SPC) for PAT in pediatric brain tumor patients. Two brain-specific models for SPC induction were applied in five cases to compare volumetric modulated arc therapy (VMAT), intensity modulated proton therapy (IMPT) and PAT surrogate plans. The PAT integral dose was reduced by a median of 29% compared to VMAT, and 17% compared to IMPT. For both models, the estimated SPC risks were consistently the lowest for PAT.

Ejemplares similares